-
Je něco špatně v tomto záznamu ?
MicroRNAs targeting EGFR signalling pathway in colorectal cancer
J. Mlcochova, P. Faltejskova, R. Nemecek, M. Svoboda, O. Slaby,
Jazyk angličtina Země Německo
Typ dokumentu časopisecké články, práce podpořená grantem, přehledy
Grantová podpora
NT13549
MZ0
CEP - Centrální evidence projektů
NT13860
MZ0
CEP - Centrální evidence projektů
Digitální knihovna NLK
Plný text - Článek
Zdroj
NLK
PubMed Central
od 1979
ProQuest Central
od 2012-01-01 do 2017-12-31
Medline Complete (EBSCOhost)
od 2003-04-01
Health & Medicine (ProQuest)
od 2012-01-01 do 2017-12-31
Public Health Database (ProQuest)
od 2012-01-01 do 2017-12-31
ROAD: Directory of Open Access Scholarly Resources
od 1997
- MeSH
- erbB receptory genetika metabolismus MeSH
- kolorektální nádory genetika metabolismus MeSH
- lidé MeSH
- mikro RNA genetika MeSH
- nádorové biomarkery genetika MeSH
- proteinkinasy genetika metabolismus MeSH
- regulace genové exprese u nádorů MeSH
- RNA interference MeSH
- signální transdukce MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- přehledy MeSH
MicroRNAs (miRNAs) are short, 18-25-nucleotide long, non-coding single-stranded RNAs, which are capable to regulate gene expression on post-transcriptional level through binding to their target protein-encoding mRNAs. miRNAs regulate individual components of multiple oncogenic pathways. One of them is epidermal growth factor receptor (EGFR) signalling pathway that regulates cell proliferation, differentiation, migration, angiogenesis and apoptosis. All these processes are deregulated in colorectal cancer (CRC). Moreover, EGFR has been validated as the therapeutic target in CRC, and monoclonal antibodies cetuximab and panitumumab are used in the therapy of patients with metastatic CRC. Because of the extensive involvement of miRNAs in the regulation of EGFR signalling, it seems they could also serve as promising predictive biomarkers to anti-EGFR therapy. In this review, we summarize current knowledge about miRNAs targeting EGFR signalling pathway, their functioning in CRC pathogenesis and potential usage as biomarkers.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc14040678
- 003
- CZ-PrNML
- 005
- 20191029134847.0
- 007
- ta
- 008
- 140107s2013 gw f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s00432-013-1470-9 $2 doi
- 035 __
- $a (PubMed)23817698
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a gw
- 100 1_
- $a Mlčochová, Jitka $7 _AN065407
- 245 10
- $a MicroRNAs targeting EGFR signalling pathway in colorectal cancer / $c J. Mlcochova, P. Faltejskova, R. Nemecek, M. Svoboda, O. Slaby,
- 520 9_
- $a MicroRNAs (miRNAs) are short, 18-25-nucleotide long, non-coding single-stranded RNAs, which are capable to regulate gene expression on post-transcriptional level through binding to their target protein-encoding mRNAs. miRNAs regulate individual components of multiple oncogenic pathways. One of them is epidermal growth factor receptor (EGFR) signalling pathway that regulates cell proliferation, differentiation, migration, angiogenesis and apoptosis. All these processes are deregulated in colorectal cancer (CRC). Moreover, EGFR has been validated as the therapeutic target in CRC, and monoclonal antibodies cetuximab and panitumumab are used in the therapy of patients with metastatic CRC. Because of the extensive involvement of miRNAs in the regulation of EGFR signalling, it seems they could also serve as promising predictive biomarkers to anti-EGFR therapy. In this review, we summarize current knowledge about miRNAs targeting EGFR signalling pathway, their functioning in CRC pathogenesis and potential usage as biomarkers.
- 650 _2
- $a kolorektální nádory $x genetika $x metabolismus $7 D015179
- 650 _2
- $a regulace genové exprese u nádorů $7 D015972
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mikro RNA $x genetika $7 D035683
- 650 _2
- $a proteinkinasy $x genetika $x metabolismus $7 D011494
- 650 _2
- $a RNA interference $7 D034622
- 650 _2
- $a erbB receptory $x genetika $x metabolismus $7 D066246
- 650 _2
- $a signální transdukce $7 D015398
- 650 _2
- $a nádorové biomarkery $x genetika $7 D014408
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Vychytilová, Petra, $u - $d 1987- $7 xx0165184
- 700 1_
- $a Němeček, Radim $u - $7 xx0128809
- 700 1_
- $a Svoboda, Marek, $u - $d 1975- $7 xx0098478
- 700 1_
- $a Slabý, Ondřej, $u - $d 1981- $7 js20030220015
- 773 0_
- $w MED00009972 $t Journal of cancer research and clinical oncology $x 1432-1335 $g Roč. 139, č. 10 (2013), s. 1615-1624
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/23817698 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20140107 $b ABA008
- 991 __
- $a 20191029135326 $b ABA008
- 999 __
- $a ok $b bmc $g 1005074 $s 839190
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2013 $b 139 $c 10 $d 1615-1624 $i 1432-1335 $m Journal of cancer research and clinical oncology $n J Cancer Res Clin Oncol $x MED00009972
- GRA __
- $a NT13549 $p MZ0
- GRA __
- $a NT13860 $p MZ0
- LZP __
- $a Pubmed-20140107